Scott J Rodig

Scott J Rodig

UNVERIFIED PROFILE

Are you Scott J Rodig?   Register this Author

Register author
Scott J Rodig

Scott J Rodig

Publications by authors named "Scott J Rodig"

Are you Scott J Rodig?   Register this Author

100Publications

4495Reads

42Profile Views

Overview of Tissue Imaging Methods.

Methods Mol Biol 2020 ;2055:455-465

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9773-2_21DOI Listing
January 2020

Detecting Gold-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Jul 1;2019(7):pdb.prot099754. Epub 2019 Jul 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099754DOI Listing
July 2019

Detecting Iodine-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Jul 1;2019(7):pdb.prot099762. Epub 2019 Jul 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099762DOI Listing
July 2019

Disruption of results in myeloproliferative neoplasms in zebrafish.

Dis Model Mech 2019 05 7;12(5). Epub 2019 May 7.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts 02215, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.035790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550042PMC
May 2019

Detecting Horseradish Peroxidase-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Apr 1;2019(4):pdb.prot099713. Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099713DOI Listing
April 2019

Detecting Alkaline Phosphatase-Labeled Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Apr 1;2019(4):pdb.prot099721. Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099721DOI Listing
April 2019

Counterstaining, Mounting, and Photographing Stained Cells.

Authors:
Scott J Rodig

Cold Spring Harb Protoc 2019 Apr 1;2019(4):pdb.prot099770. Epub 2019 Apr 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot099770DOI Listing
April 2019

Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.

Haematologica 2018 Oct 21;103(10):1679-1687. Epub 2018 Jun 21.

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.183236DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165815PMC
October 2018

A Simple and Effective Method for Flow Cytometric Study of Lymphoid Malignancies Using Needle Core Biopsy Specimens.

Cytometry B Clin Cytom 2018 09 1;94(5):637-643. Epub 2018 Apr 1.

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21634DOI Listing
September 2018

Reply to Z. Wu et al.

J Clin Oncol 2018 09 30;36(25):2657. Epub 2018 May 30.

Donna S. Neuberg, Dana-Farber Cancer Institute; and Harvard T.H. Chan School of Public Health, Boston, MA; Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; and Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9826
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9826DOI Listing
September 2018

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

J Clin Oncol 2018 04 2;36(10):942-950. Epub 2018 Feb 2.

Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine J. Pak, Sara Abdelrahman, Jing Ouyang, Philippe Armand, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Geraldine S. Pinkus, Azra H. Ligon, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer, VU University Medical Center; Jan Paul De Boer, Antoni van Leeuwenhoek Hospital, Lunenburg Phase I/II Consortium, Amsterdam, the Netherlands; Stephanie Sasse, University Hospital of Cologne, Cologne, Germany; Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY; Michelle Fanale, University of Texas MD Anderson Cancer Center, Houston, TX; Armando Santoro, Humanitas University, Rozzano, Milan; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; John Timmerman, University of California, Los Angeles Medical Center, Los Angeles, CA; Graham P. Collins, Churchill Hospital, Oxford, United Kingdom; Radhakrishnan Ramchandren, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Jonathon B. Cohen, Emory University, Atlanta, GA; John Kuruvilla, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Kerry J. Savage, British Columbia Cancer Agency Center for Lymphoid Cancer, Vancouver, British Columbia, Canada; Marek Trneny, Charles University in Prague, General University Hospital in Prague, Prague, Czech Republic; Stephen Ansell, Mayo Clinic, Rochester, MN; and Kazunobu Kato, Benedetto Farsaci, and Anne Sumbul, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877802PMC
April 2018

Implications of the tumor immune microenvironment for staging and therapeutics.

Mod Pathol 2018 02 1;31(2):214-234. Epub 2017 Dec 1.

Department of Pathology, The Johns Hopkins University SOM and Bloomberg-Kimmel Institute for Immunotherapy, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2017.156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132263PMC
February 2018

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.

Blood Adv 2017 Dec 12;1(26):2643-2654. Epub 2017 Dec 12.

Department of Pathology, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017012534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728646PMC
December 2017

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

J Clin Oncol 2017 Jun 13;35(16):1836-1844. Epub 2017 Apr 13.

Tsuyoshi Hamada, Zhi Rong Qian, Yohei Masugi, Juhong Yang, Kosuke Mima, Keisuke Kosumi, Li Liu, Yan Shi, Annacarolina da Silva, Mancang Gu, Wanwan Li, Jeffrey A. Meyerhardt, Marios Giannakis, Scott J. Rodig, Gordon J. Freeman, Charles S. Fuchs, Reiko Nishihara, and Shuji Ogino, Dana-Farber Cancer Institute and Harvard Medical School; Yin Cao, Mingyang Song, and Andrew T. Chan, Massachusetts General Hospital and Harvard Medical School; Yin Cao, Mingyang Song, Li Liu, NaNa Keum, Kana Wu, Edward L. Giovannucci, Daniel Nevo, Molin Wang, Reiko Nishihara, and Shuji Ogino, Harvard T.H. Chan School of Public Health; Jonathan A. Nowak, Xuehong Zhang, Edward L. Giovannucci, Marios Giannakis, Gordon J. Freeman, Molin Wang, Andrew T. Chan, Charles S. Fuchs, and Shuji Ogino, Brigham and Women's Hospital and Harvard Medical School, Boston; Marios Giannakis and Andrew T. Chan, Broad Institute of MIT and Harvard University, Cambridge, MA; Li Liu, Huazhong University of Science and Technology, Wuhan; Yan Shi, Chinese People's Liberation Army General Hospital, Beijing; and Mancang Gu, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455595PMC
June 2017

Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Lab Invest 2017 02 5;97(2):207-216. Epub 2016 Dec 5.

Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.2016.126DOI Listing
February 2017

Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.

Cell Stem Cell 2017 02 15;20(2):233-246.e7. Epub 2016 Dec 15.

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.stem.2016.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291795PMC
February 2017

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Immunity 2017 02;46(2):197-204

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2017.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408320PMC
February 2017

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

J Clin Oncol 2017 Jan 24;35(1):24-31. Epub 2016 Oct 24.

Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, David M. Weinstock, Scott J. Rodig, Philippe Armand, Dana-Farber Cancer Institute; Gabriel K. Griffin, Reid W. Merryman, Christine Pak, Heather Sun, Brigham and Women's Hospital; German A. Pihan, Beth Israel Deaconess Medical Center; and Aliyah R. Sohani, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455688PMC
January 2017

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Cancer Med 2016 11 17;5(11):3041-3050. Epub 2016 Oct 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.862DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119958PMC
November 2016

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

J Clin Oncol 2016 08 11;34(23):2690-7. Epub 2016 Apr 11.

Margaretha G.M. Roemer, Robert A. Redd, Heather Homer, Courtney F. Connelly, Gordon J. Freeman, Philippe Armand, Bjoern Chapuy, Donna S. Neuberg, and Margaret A. Shipp, Dana-Farber Cancer Institute; Azra H. Ligon, Heather H. Sun, and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Margaretha G.M. Roemer and Daphne de Jong, VU University Medical Center, Amsterdam, the Netherlands; and Ranjana H. Advani, Yasodha Natkunam, Sarah E. Daadi, and Richard T. Hoppe, Stanford University Medical Center, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.4482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019753PMC
August 2016

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

J Clin Oncol 2016 08 6;34(23):2698-704. Epub 2016 Jun 6.

Alexander M. Lesokhin and Deepika Cattry, Memorial Sloan Kettering Cancer Center; Alexander M. Lesokhin, Weill Cornell Medical College, New York, NY; Stephen M. Ansell, Mayo Clinic, Rochester, MN; Philippe Armand, Bjoern Chapuy, Gordon J. Freeman, Scott J. Rodig, and Margaret A. Shipp, Dana-Farber Cancer Institute; David Avigan, Beth Israel Deaconess Medical Center; Azra H. Ligon and Scott J. Rodig, Brigham and Women's Hospital, Boston, MA; Emma C. Scott, Oregon Health & Science University Knight Cancer Institute, Portland, OR; Ahmad Halwani, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Martin Gutierrez, Hackensack University Medical Center, Hackensack; Lili Zhu, Joseph F. Grosso, and M. Brigid Bradley Garelik, Bristol-Myers Squibb, Princeton, NJ; Michael M. Millenson, Fox Chase Cancer Center; Adam D. Cohen and Stephen J. Schuster, University of Pennsylvania, Philadelphia, PA; Daniel Lebovic, University of Michigan, Ann Arbor, MI; Madhav Dhodapkar, Yale Cancer Center, New Haven, CT; Ivan Borrello, Johns Hopkins University School of Medicine, Baltimore, MD; and John Timmerman, University of California, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9789DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019749PMC
August 2016

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Cancer Immunol Res 2016 08 16;4(8):679-87. Epub 2016 Jun 16.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0031DOI Listing
August 2016

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

N Engl J Med 2016 Jul;375(2):143-53

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (M.S.D., H.T.K., P.B., R.L., A.S., A.P.L., M.H., M.S., F.S.H., C.J.W., V.T.H., C. Cutler, J.K., E.P.A., J.H.A., P.A., J.R., R.J.S.), the Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center and Harvard Medical School (D.A.), the Bone Marrow Transplant Program, Massachusetts General Hospital Cancer Center and Harvard Medical School (Y.-B.C.), the Departments of Dermatology (N.R.L.) and Pathology (S.R.G., J.L.H., S.J.R.), Dana-Farber and Brigham and Women's Cancer Center, and the Dana-Farber Cancer Institute, Center for Molecular Oncologic Pathology (M.B., C.W.Z.) - all in Boston; Broad Institute of Massachusetts Institute of Technology and Harvard (P.B., C.J.W.) and Neon Therapeutics (M.S.R.) - both in Cambridge; the Blood and Marrow Transplant Program, University of California, San Diego, Moores Cancer Center, La Jolla (C. Costello, E.D.B.); Colorado Blood Cancer Institute, Denver (P.M.); Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (H.S.); and the Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta (A.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1601202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149459PMC
July 2016

RelA-Induced Interferon Response Negatively Regulates Proliferation.

PLoS One 2015 13;10(10):e0140243. Epub 2015 Oct 13.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140243PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604146PMC
June 2016

The Role of Surgical Pathology in Guiding Cancer Immunotherapy.

Annu Rev Pathol 2016 05;11:313-41

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115; email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-pathol-012615-044125DOI Listing
May 2016

Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.

Am J Surg Pathol 2016 Apr;40(4):443-53

*Department of Pathology, Brigham and Women's Hospital Departments of †Medical Oncology ‡Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000590DOI Listing
April 2016

MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.

Am J Clin Pathol 2016 Feb 1;145(2):166-79. Epub 2016 Feb 1.

From the Department of Pathology, Brigham and Women's Hospital, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqv028DOI Listing
February 2016

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

J Thorac Oncol 2015 Dec;10(12):1726-35

*Department of Medical Oncology, †Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; ‡Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; §Harvard Medical School, Boston, Massachusetts; ‖Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts. ¶Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and #Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000687DOI Listing
December 2015

Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations.

Semin Diagn Pathol 2015 Sep 4;32(5):381-91. Epub 2015 Feb 4.

Department of Pathology, Brigham and Women 's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2015.02.016DOI Listing
September 2015

Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.

Histopathology 2015 Jul 20;67(1):81-9. Epub 2015 Jan 20.

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12622DOI Listing
July 2015

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Clin Cancer Res 2015 Jun 3;21(12):2851-60. Epub 2015 Mar 3.

Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3112DOI Listing
June 2015

The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.

Cell 2015 Apr 2;161(2):319-32. Epub 2015 Apr 2.

Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.02.043DOI Listing
April 2015

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Br J Haematol 2015 Jan 26;168(2):230-8. Epub 2014 Sep 26.

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Haematology, UCL Cancer Institute, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303513PMC
January 2015

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

N Engl J Med 2015 Jan 6;372(4):311-9. Epub 2014 Dec 6.

From the Mayo Clinic, Rochester, MN (S.M.A.); Memorial Sloan Kettering Cancer Center (A.M.L., D.C.) and Weill Cornell Medical College (A.M.L.) - both in New York; Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore (I.B.); University of Utah Huntsman Cancer Institute, Salt Lake City (A.H.); Oregon Health and Science University and the Knight Cancer Institute, Portland (E.C.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack (M.G.), and Bristol-Myers Squibb, Lawrenceville (L.Z., J.F.G., S.Y.K.) - both in New Jersey; Abramson Cancer Center, University of Pennsylvania (S.J.S.), and Fox Chase Cancer Center (M.M.M.) - both in Philadelphia; Dana-Farber Cancer Institute (G.J.F., B.C., M.A.S., P.A.) Brigham and Women's Hospital (S.J.R., A.H.L.), and Harvard Medical School (G.J.F., B.C., M.A.S., P.A., S.J.R., A.H.L.) - all in Boston; and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles (J.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348009PMC
January 2015

High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.

Mod Pathol 2014 Nov 25;27(11):1447-54. Epub 2014 Apr 25.

Department of Pathology, WRN244, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2014.69DOI Listing
November 2014

Profile of CD103 expression in T-cell neoplasms: immunoreactivity is not restricted to enteropathy-associated T-cell lymphoma.

Am J Surg Pathol 2014 Nov;38(11):1557-70

*Department of Pathology, Brigham and Women's Hospital and Harvard Medical School †Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston §Department of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA ‡Department of Pathology, UCLA Medical Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000296DOI Listing
November 2014

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

Am J Surg Pathol 2014 Jun;38(6):768-75

*Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH †Department of Pathology, University of California Los Angeles, Los Angeles, CA ‡Department of Anatomic Pathology ¶Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN §Department of Pathology, Brigham and Women's Hospital, Boston, MA ∥British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085049PMC
June 2014

MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).

Am J Surg Pathol 2014 Jun;38(6):776-83

Departments of *Pathology †Medicine, Division of Hematology/Oncology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester ‡Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2014/06000/MYC_Protein_Exp
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000213DOI Listing
June 2014

Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.

Clin Cancer Res 2014 May 7;20(10):2674-83. Epub 2014 Mar 7.

Authors' Affiliations: Medical Oncology, Dana-Farber Cancer Institute; Section of Computational Biomedicine, Boston University School of Medicine; and Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084704PMC
May 2014

Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.

Blood 2014 Feb 18;123(6):884-93. Epub 2013 Dec 18.

Department of Pediatric Oncology and the Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-04-499079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916879PMC
February 2014

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Cancer Discov 2013 Dec 27;3(12):1355-63. Epub 2013 Sep 27.

Departments of 1Medicine and 2Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute; 3Harvard Medical School; 4Ludwig Institute for Cancer Research; 5Department of Neurosurgery, Massachusetts General Hospital; 6Belfer Institute for Applied Cancer Science; 7Department of Pathology, Brigham and Women's Hospital, Boston; 8Broad Institute, Cambridge, Massachusetts; 9UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and 10Department of Molecular Pharmacology and Therapeutics, Oncology Institute, Loyola University, Chicago, Illinois; 11Department of Physiology, University of Valencia, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864135PMC
December 2013

Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.

Cancer 2013 Oct 6;119(19):3472-8. Epub 2013 Aug 6.

Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28249DOI Listing
October 2013

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Am J Surg Pathol 2013 Sep;37(9):1441-9

*Department of Pathology, Brigham and Women's Hospital †Lowe Center for Thoracic Oncology ‡Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e3182960fa7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831351PMC
September 2013

MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.

Elife 2013 Jul 16;2:e00825. Epub 2013 Jul 16.

Institute of Transfusion Medicine , University Hospital Essen , Essen , Germany ; Department of Pediatric Oncology , Dana-Farber Cancer Institute , Boston , United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7554/eLife.00825DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713455PMC
July 2013